caduet
pfizer europe ma eeig - amlodipinas/atorvastatinas - plėvele dengtos tabletės - 5 mg/10 mg; 10 mg/10 mg - atorvastatin and amlodipine
fluorescite
alcon farmaceutika d.o.o. - fluoresceinas - injekcinis tirpalas - 100 mg/ml - fluorescein
bisoprololfumaraat aurobindo
lex ano, uab - bizoprololio fumaratas - plėvele dengtos tabletės - 5 mg - bisoprolol
bisoprolol actiofarma
actiofarma, uab - bizoprololio fumaratas - plėvele dengtos tabletės - 2,5 mg - bisoprolol
zonsiloc
lex ano, uab - bizoprololio fumaratas - plėvele dengtos tabletės - 2,5 mg - bisoprolol
cosimprel
les laboratoires servier - bizoprololio fumaratas/perindoprilio argininas - plėvele dengtos tabletės - 10 mg/10 mg; 10 mg/5 mg; 5 mg/10 mg; 5 mg/5 mg - perindopril and bisoprolol
cosimprel
lex ano, uab - bizoprololio fumaratas/perindoprilio argininas - plėvele dengtos tabletės - 5 mg/5 mg - perindopril and bisoprolol
hipokin
g.l. pharma gmbh - tiapridas - tabletės - 100 mg - tiapride
tenaxum
les laboratoires servier - rilmenidinas - tabletės - 1 mg - rilmenidine
xtandi
astellas pharma europe b.v. - enzalutamidas - prostatos navikai - endokrininė terapija - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.